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1. Introduction 
The prevalence of Alzheimer’s disease (AD), the most common form of dementia, is rising 
rapidly worldwide. A seemingly imminent epidemic is predicted to have wide reaching 
societal and economic consequences, becoming the leading health issue for many countries 
by the middle of this century. This epidemic is driven by an ageing world population in 
combination with a lack of disease modifying treatments or preventive strategies. The 
popular amyloid cascade hypothesis suggests that AD is precipitated by the dysregulated 
metabolism of the amyloid precursor protein resulting in the accumulation of the beta-
amyloid peptide (A) in the brain. This hypothesis is the basis for most experimental 
treatments currently in clinical trials. However, not all evidence supports a precipitating role 
of abnormal A accumulation in the common forms of AD.  
The completion of the human genome project in 2001 has ushered in a dramatic increase in 
the technologies available to biologists and these have been applied to understanding the 
pathogenesis of complex disorders, like AD. Genome-wide association and expression 
(transcriptomic) studies are now commonplace creating a more immediate and dynamic, 
but invariably more complex, research environment. 
Transcriptomic studies in particular have the potential to greatly influence our 
understanding of complex diseases like AD, but to date they have provided quite discordant 
results. There are a number of potential reasons for this including our incomplete 
understanding of the complex nature of the human brain at the molecular level. It is now 
known that the evolutionary advances in our cognitive capacity have largely originated at 
the level of transcription with substantial increases in both coding and non-coding RNA 
variants. Until recently transcriptomic platforms only assayed a proportion of the coding 
RNA species, but with the introduction of next generation sequencing the whole 
transcriptome, both coding and non-coding, can now be investigated.  
In this chapter we undertake a review of the clinical and pathological characteristics of AD 
before considering the impact of new technologies on AD research and their future role in 
finding a cure for this important disease. 
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2. Alzheimer’s disease  
2.1 Overview 
The term dementia encapsulates a number of separate diseases that clinically manifest as a 
progressive decline in cognitive function. Alzheimer’s disease (AD) is the most common 
form of dementia accounting for approximately 60% of all cases. It is estimated that the 
current 36 million sufferers worldwide will increase to 115 million by 2050 (Alzheimer's 
Disease International, 2009). In countries like Australia, dementia will become the number 
one health cost by the middle of this century exceeding both heart disease and cancer 
(Access Economics, 2009). These surprising predictions result from the additive effects of an 
ageing world population, the duration of the disease and the extended period where the 
patient is totally dependent on caregivers. The societal trend in Western countries towards 
professional aged care services accounts for the majority of the current and predicted costs. 
 More importantly, AD is a cruel disease that robs patients of their sense of self and places 
considerable physical and psychological strain on caregivers, who are often isolated from 
society themselves. As the currently available treatments only provide transient 
improvement, an AD epidemic will only be halted with the development of new therapies. 
It has been predicted that a novel therapeutic agent that delays disease onset and 
progression by just one year would result in nine million fewer cases by 2050 (Brookmeyer 
et al., 2007).  
The other approach to reducing the worldwide burden of AD is prevention. This would be 
based on either avoiding identified risk factors or augmenting the impact of protective 
factors. Unfortunately finding such factors through epidemiological studies has proved 
extremely difficult to date.  
The completion of the human genome project in 2001 ushered in a dramatic increase in the 
technologies that have subsequently been applied to understanding the pathogenesis of 
complex disorders, like AD. Genome-wide association and expression studies are now 
commonplace in AD research creating a more immediate and dynamic research 
environment. The application of these technologies to clinical, pathological and 
epidemiological studies of AD is starting to bear fruit although effective treatments are not 
necessarily close at hand. 
2.2 The history of AD 
Emil Kraepelin first used the name Alzheimer’s disease in 1910 in recognition of Alois 
Alzheimer (1864-1915), the German psychiatrist and neuropathologist, who had originally 
described the clinical and pathological features of the disease. Kraepelin was keen to make 
the distinction between the presenile form of dementia (described by Alzheimer) and the 
more common senile variant. 
Alzheimer's findings were originally published in 1907, in the form of a conference abstract 
where he described a delusional woman (Auguste D) who had slowly lost her cognitive 
function and died at 55 years of age (Alzheimer, 1907). According to a later translation of the 
original manuscript Auguste D suffered from reduced comprehension and memory as well 
as psychotic symptoms including paranoia that resulted in her psychosocial impairment 
(Maurer et al., 1997). The first formal description of Auguste D was by Perusini in 1909 in a 
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textbook edited by Nissl and Alzheimer (Perusini, 1909). Alzheimer himself only published 
a detailed clinical and pathological report in 1911 along with his findings from a second case 
(Johan F) (Alzheimer, 1911). Interestingly Alzheimer described Auguste D as having both 
the pathologies that we now know as plaques and tangles in her cerebral cortex but Johan F 
as having only plaques. Graeber and colleagues re-examined Alzheimer’s original sections 
90 years later and confirmed the original histopathological findings for Johann F (Graeber et 
al., 1997) and Auguste D (Graeber et al., 1998). In accordance with Kraepelin’s original 
classification the term Alzheimer’s disease or Alzheimer’s presenile dementia continued to 
be exclusively used for a rare disease of mid-life until the 1970’s when neuropathologists 
realised that the more common senile dementia and the type described by Alzheimer were 
indistinguishable (Terry and Katzman, 1983). 
2.3 Prevalence and cost 
The mean age at onset of AD is around 75 years of age and the overall prevalence is about 
1% in most developed nations. If AD prevalence is divided into different age bands then we 
see a rapid increase from 1% in the 60-64 year age group to greater than 25% in individuals 
over 85 years of age (Jorm and Jolley, 1998).  
A comprehensive estimate of worldwide prevalence was recently reported with age- and 
gender-specific prevalence and projections out to 2050 (Alzheimer's Disease International, 
2009). This suggested that the current worldwide burden of 35.6 million dementia sufferers 
would nearly double every 20 years, to 65.7 million in 2030, and 115.4 million in 2050. The 
authors attributed this increase to population growth and demographic ageing. 
Alzheimer's Disease International (ADI) has addressed the current cost of dementia 
worldwide and predicted its future economic impact (Alzheimer's Disease International, 
2010). They suggested that the currents cost of US$604 billion would increase by 85% to 
US$1000 billion by 2030. They noted considerable disparity between high-income and low-
income countries largely due to formal care facilities in the former, rather than direct health 
costs. Direct health costs amounted to only 16% of the average $32,000 per annum costs in 
the USA. ADI considered that stigmatisation played a role here where cognitive decline was 
often the precipitant for institutionalisation as opposed to individuals with severe physical 
disabilities who are often supported at home by community services. 
In terms of care-giving an important indirect effect of AD and dementia that may often be 
missed in such reports is the physical and psychological toll on the caregivers themselves. It 
is estimated that a person with dementia requires more than 7 hours of close supervision per 
day (Wimo et al., 2007). Caregivers are commonly spouses or first-degree relatives, and for 
long periods of time will be as socially isolated as the patients themselves. They are 
estimated to experience between a three- and 40-fold increase in their risk of major 
depression (Cuijpers, 2005). Caregivers who choose to support a dementia patient at home 
also are likely to suffer a huge financial burden, through lost of income, disability-friendly 
renovations and the hiring of respite care. These costs are only partially off set by 
government allowances or pensions in most cases. 
2.4 Clinical findings 
The term dementia refers to the main clinical manifestation of AD but also occurs with other 
diseases including frontotemporal dementia (FTD), vascular dementia (VaD) and dementia 
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with Lewy bodies (DLB). Dementia is a progressive decline in cognition that impairs social 
and/or occupational function. The deficits in a particular individual will reflect the regions 
in which neuronal loss occurs.  
AD sufferers will usually present to a general physician because of their own concern about 
deteriorating cognition or the concerns of an informant (often their spouse or work 
colleague). A general physician may refer the patient to a specialist geriatrician or 
neurologist but many patients remain under the primary care of their general practitioners. 
The loss of short-term memory is often the earliest cognitive phenotype for AD (Dubois and 
Albert, 2004).  
2.5 Diagnosis 
The criteria for a clinical diagnosis of AD were established in 1984 and have remained 
unchanged for the past 27 years (McKhann et al., 1984). The diagnosis of AD is currently 
based on clinical examination and neuropsychological testing although a definitive 
diagnosis can only made by postmortem examination. However, the latter is uncommon 
outside a research setting. A diagnosis of ‘Probable AD’ is made when there is worsening 
memory function, particularly episodic memory, accompanied by deficits in two or more 
other cognitive domains such as executive function, attention, language or visuospatial 
skills.  
A diagnosis of AD would be supported by a positive family history, a normal 
electroencephalogram, normal cerebrospinal fluid (CSF) analysis and atrophy on computer-
assisted tomography (CAT) imaging (the only neuroimaging modality available in 1984). An 
alternative diagnosis of ‘possible AD’ was suggested when there was a general dementia 
syndrome but with variations in onset and clinical course (McKhann et al., 1984). Exclusion 
criteria for AD included the rapid onset of dementia, an early prominence of gait 
abnormalities or a focal neurological deficit. 
In 2011, these criteria were updated, prompted by some inconsistent clinical-pathological 
correlations and a need to incorporate the likely prodromal periods of AD and biomarkers 
(biological markers) (Jack et al., 2011). The new criteria propose a continuum of impairment 
but also delineate three stages along this spectrum: preclinical AD, mild cognitive 
impairment (MCI) and clinical AD. The basis for these stages is that the pathophysiological 
process of AD can be reliably represented by biomarkers. The existing ‘probable’ and 
‘possible’ categories are now expanded to (1) Probable AD dementia, (2) Possible AD 
dementia, and (3) Dementia with evidence of the AD pathophysiological process. An 
example of the latter would be an individual with a less typical clinical presentation but 
with AD-like biomarkers on their neuroimaging or CSF analysis (McKhann et al., 2011). 
However, biomarkers continue to only support a clinical diagnosis of AD while definitive 
diagnosis still requires a postmortem examination.  
The differentiation of AD from MCI rests on the determination of whether or not there is 
significant interference in the ability to function at work or in usual daily activities (Albert et 
al., 2011). MCI is not a definite stage on the progression to AD because some individuals will 
never develop dementia or will develop other forms such as VaD. However, pathological 
studies suggest that the majority of individuals with MCI have typical AD pathology, but 
just in a lesser amount to those who become clinically demented (Haroutunian et al., 2009). 
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The definition of preclinical AD remains a research-only paradigm based on the promise 
that biomarkers faithfully reflect the underlying pathophysiological processes (Sperling et 
al., 2011). As will be discussed below this preclinical diagnostic paradigm is firmly based on 
one, albeit prominent, working hypothesis for AD pathogenesis. 
2.6 Clinical heterogeneity 
The review of the clinical diagnostic criteria was prompted in part by increasing reports of 
variations in the classic presentation of AD. It has even been suggested that the term 
Alzheimer’s syndrome is more appropriate than AD (Zellner et al., 2009). In addition to the 
classic amnestic presentation of AD described above, a “visual variant” of AD, often called 
posterior cortical atrophy, a “language variant” called logopenic/phonological aphasia 
(Gorno-Tempini et al., 2011) and a frontal/behavioural variant are occasionally observed 
(Johnson et al., 1999). The latter two are also considered sub-categories of frontotemporal 
dementia hinting that there might be considerable overlap in clinicopathological correlates 
between the current clinical dementia categories. This is supported by a recent study that 
found AD to be the primary pathological diagnosis in a range of focal cortical syndromes 
including 50% of corticobasal disease and 44% progressive non-fluent aphasia, another 
language variant of frontotemoporal dementia (Alladi et al., 2007). This clinical or 
phenotypic heterogeneity in AD suggests variation in both aetiology and pathogenesis and 
the potential ramifications of this will be discussed in greater detail below. 
2.7 Current treatment options 
There are two classes of drugs that are currently used to treat moderate to severe cases of AD. 
They are the acetylcholinesterases inhibitors (ChEIs) and glutaminergic receptor antagonists. 
The cholinergic (acetylcholine producing) neurons of the basal forebrain nuclei such as the 
nucleus basalis of Meynert are among the earliest lost in AD (Cullen and Halliday, 1998). 
These neurons synapse in the prefrontal cortex and the hippocampus where they release 
acetylcholine to modulate circuits involved in learning and memory (Gold, 2003).  
Acetylcholinesterases are enzymes responsible for the rapid breakdown of acetylcholine in 
the synaptic cleft. ChEIs are postulated to maximise the residual acetylcholine modulating 
these memory circuits in the AD brain and there are three types in current use donepezil, 
rivastigmine and galantamine. Meta-analyses of randomised control trials for the three 
ChEIs suggest that all show moderate improvements in cognitive function over placebo but 
the incidence of adverse events is lowest for donepezil (Birks, 2006; Hansen et al., 2008)  
The other drug in common use is called memantine, a low affinity glutamate NMDA 
receptor antagonist. The postulated mechanism of action for memantine is the prevention of 
glutamate-mediated excitatory neurotoxicity (McShane et al., 2006). As with the ChEIs, 
meta-analyses report a significant but marginal improvement (Raina et al., 2008) with 
particular attenuation of behavioural symptoms (Gauthier et al., 2008). Memantine is less 
efficacious in mild to moderate compared to severe AD (MMSE >15) (McShane et al., 2006; 
Schneider et al., 2011). 
Unfortunately there is no evidence that either of these treatments significantly alters disease 
progression (Golde et al., 2011). Hence there is enormous research effort aimed at finding 
alternative treatment strategies, some of which have already reached Phase II and III human 
clinical trials. These potential treatments are discussed below. 
www.intechopen.com
 
Neuroscience – Dealing with Frontiers 394 
2.8 Neuropathology 
As discussed in the section above, a definitive diagnosis of AD can only be made at 
postmortem examination. Unfortunately the number of autopsies has declined markedly in 
the last three decades depriving clinicians and researchers alike of an important source of 
medical knowledge. Neuropathological examinations are now largely restricted to a 
research environment with the potential issue that clinically confirmed cases are not be 
representative of the AD spectrum in the greater population.  
As with the clinical diagnosis, there are established criteria for the pathological diagnosis of 
AD (Hyman and Trojanowski, 1997) although these too are currently being revised. 
Interestingly, although postmortem examination is required for a definitive diagnosis of AD 
the pathological criteria again, only suggests that AD is ‘probable’ or ‘possible’. In order to 
understand how these criteria have been derived it is useful to give a brief overview of the 
characteristic or pathognomonic aspects of AD.  
2.8.1 Gross pathology 
The gross pathology of the end-stage AD brain is characterised by widespread atrophy due to 
the extensive neuronal loss. There is narrowing of gyri and widening of sulci with atrophy of 
the temporal cortices and a disproportionate atrophy of the entorhinal cortex, amygdala and 
hippocampus in particular. The remaining cortical regions are generally atrophic, but to a 
lesser extent than the temporal lobe, although there are also regions seemingly spared from 
neuronal loss such as the inferior frontal cortex (Halliday et al., 2003) (Fig. 1(a-b)).  
2.8.2 Plaques and tangles 
The neuropathology of AD is characterised by two pathognomonic entities; the 
intraneuronal neurofibrillary tangle (NFT) and the extracellular plaque. NFTs are chiefly 
composed of hyperphosphorylated fibrillar forms of a protein called microtubule associated 
protein tau (MAPT or tau), while plaques are predominantly composed of fibrils of peptides 
collectively termed beta-amyloid (Aǃ) (Fig. 1 (c-d)).  
For most individuals, there is a good correlation between spread of NFT pathology from the 
medial temporal lobe to the association and finally primary cortices, and the probability of 
dementia (Newell et al., 1999). In comparison the regional distribution of plaques tends to be 
highly variable between patients (Braak and Braak, 1991). Similarly plaques vary more in 
their cortical laminar pattern whereas NFTs are found mainly in layers III and V coinciding 
with the corticocortical projection (pyramidal) neurons (Lewis et al., 1987). Plaques also vary 
in their structure and are referred to as ‘diffuse’ (lacking associated inflammatory cells and 
dystrophic neurites) and ‘cored’ or ‘neuritic’ plaques. It is generally considered that diffuse 
plaques eventually become cored but an alternative explanation suggests that the amyloid 
of diffuse and cored plaques are derived from blood vesssels and neurons respectively 
(D'Andrea and Nagele, 2010).  
Extracellular A deposition is considered to be the most likely precipitating event in the 
disease (Hardy and Selkoe, 2002). In comparison, NFT formation is a subsequent but 
necessary step in neurodegeneration of AD with intracellular tangles becoming ‘ghost 
tangles’ when the neuron eventually succumbs and the insoluble tau protein is left behind in 
the parenchyma. Presumably the brain macrophages find these extracellular tangles too 
difficult to phagocytose or they are relatively inert. 
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Fig. 1. The neuropathological features of Alzheimer’s disease. A series of macro-and 
microscopic images show the pathological features of Alzheimer’s disease (a) A lateral view 
of the right cerebral hemisphere shows extensive atrophy of the temporal and frontal lobes. 
There are also regions spared in this case including the precentral (Pr) and and postcentral 
(Po) gyri and the occipital pole (O), size bar = 2cm (b) A coronal view at the level of the 
lateral geniculate body demonstrates the severe atrophy in the temporal lobe including the 
hippocampus (h), along with enlargement of the Sylvian fissure, and third and lateral 
ventricles, size bar = 2cm (c) A modified Bielschowsky’s silver stain shows neurofibrillary 
tangles in two cortical pyramidal neurons, magnification = 400x and (d) a cored plaque, 
with its dense amyloid core surrounded by diffuse amyloid, dystrophic neurites and cellular 
debris, magnification = 200x. 
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2.8.3 Neuronal loss 
The hippocampal CA1 (1st cornus ammonis or Ammon’s horn) region experiences the 
greatest loss of neurons in AD of approximately 70%. The CA1 is anatomically and 
functional connected to the entorhinal cortex where the earliest development of NFTs and 
neuronal loss in AD is thought to occur. The locus coeruleus (noradrenalin production), 
nucleus basalis of Meynert and the Raphe nuclei can also experience losses of greater than 
50% as does the majority of the temporal lobe (Kril and Halliday, 2001). The loss of neurons 
in the nucleus basalis of Meynert is similar to the number of ghost tangles but in the 
hippocampus (Kril et al., 2002) and entorhinal cortex (Gomez-Isla et al., 1996) neuron loss 
actually exceeds the number of ghost tangle suggesting other neurodegenerative 
mechanisms are at work. The spread of pathology and associated neuronal loss in AD 
dictates the symptomology. The reader will note the early involvement of the hippocampus, 
a key region in both memory generation and consolidation. Interestingly the eventual 
spread of AD pathology mirrors the anatomical boundaries of the default network – the 
“brain system active when individuals are not focused on their external environment” 
(Buckner et al., 2008). The default network is involves with the process of internal mentation 
or self-relevant mental simulation. This peculiarly human activity could explain the regional 
selectivity of neuronal loss in AD while deficits in the network are certainly consistent with 
the loss of self-awareness in moderate to severe stages of the disease (Buckner et al., 2008). 
2.8.4 Chronic inflammation 
AD is also characterised by a chronic inflammatory process that is commonly called reactive 
gliosis. Markers of inflammation such as MHC II expression are higher in demented patients 
than those in nondemented individuals with AD pathology and may be better correlated 
with synaptic dysfunction than either plaques or NFTs (Lue et al., 1996). Essentially when 
we refer to reactive gliosis we mean reactive microgliosis, a hyperplastic and hypertrophic 
response of the resident macrophages in the brain. There is also astrocyte pathology but this 
remains less well defined in AD (Beach and McGeer, 1988). The increased expression of the 
cytosketal protein glial fibrillary acidic protein (GFAP) that characterised ’reactive’ 
astrocytes has been described in AD brains although this was not correlated with either 
plaques or NFTs (Simpson et al.). Microglia are originally derived from the haemopoietic 
system and migrate to the brain during the early embryological period. Reactive microglia 
in AD are closely associated with plaques and studies with immunomodulatory therapies 
suggest that they are relatively effective, at least early in the disease process, at 
phagocytosing A plaques (Perlmutter et al., 1990; Edison et al., 2008). However 
neuroinflammation appears to exacerbate AD pathogenesis (Krause and Muller, 2010) and 
anti-inflammatory medication use is associated with a reduced risk of AD (Vlad et al., 2008). 
This apparent paradox might be explained by microglia initially serving a protective role 
but eventually becoming overstimulated and producing excessive reactive oxygen species 
that lead to neurotoxicity (Innamorato et al., 2009). Nevertheless anti-inflammatory 
medications do not reduce the progression of AD pathology (Halliday et al., 2000). As 
microglia are now known to have physiological functions in the brain such the maintenance 
of synaptic plasticity and it has been suggested that they may be more ‘victim’ than ‘villain’ 
in AD (Graeber and Streit, 2010).  
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2.8.5 Diagnostic criteria 
The current pathological criteria are based on the quantity of both plaques and NFTs 
(Hyman and Trojanowski, 1997) and incorporate a staging scheme for the neuropathological 
progression of NFTs (‘Braak staging scheme’) (Braak and Braak, 1991). The likelihood of AD 
is high if there are frequent neocortical plaques and NFTs consistent with Braak stage V/VI; 
is intermediate if plaques are moderate with Braak stage III/VI and low if neocortical 
plaques are sparse with Braak stage is I/II. 
2.9 The ageing brain 
One of the reasons that the AD neuropathological diagnostic criteria are a probability scale 
is the occurrence of both plaques and NFTs, either independently or together, in a 
proportion of aged subjects without dementia. Diffuse plaques are seen in as many as 30% 
of all brains examined (Braak and Braak, 1997; Davis et al., 1999). A similar percentage of 
cognitively normal individuals have tau-positive neuritic pathology (Knopman et al., 2003) 
although tau pathology confined to the hippocampal formation appears to be seen in most, 
if not all, aged brains (Troncoso et al., 1996). As discussed above the quantity of AD 
pathology tends to correlate relatively closely to the level of dementia and many researchers 
consider that the presence of mild pathology is representative of preclinical AD (Price et al., 
2009). Dementia then occurs when the quantity of AD pathology crosses a particular 
threshold. Two issues with this idea are that some individuals with A will not develop 
dementia prior to death (incidental AD pathology) and these A clinicopathological 
correlations tend to breakdown in the oldest old (>90 years of age) (Kril, 2009). 
As will be discussed further below, the common occurrence of incidental AD and AD-type 
pathology in nondemented controls could also be a factor in the small effect sizes and lack of 
reproducibility seen in AD association studies to date (Sutherland et al., 2011b). 
3. The genomic era and its new technologies 
The last decade has seen an incredible advance in the biologist’s armamentarium for 
investigating complex diseases. This biological revolution has its roots in the development 
of molecular biology techniques such as gene cloning using restriction enzymes (Nathans 
and Smith, 1975), DNA hybridisation (Southern, 1975), Sanger sequencing (Sanger et al., 
1977) and the polymerase chain reaction (PCR) (Saiki et al., 1985; Mullis and Faloona, 1987). 
However, it was human genome project that provided the real impetus.  
3.1 The human genome project 
The human genome project began in 1989 and was initially headed by the co-founder of 
DNA’s structure and Nobel laureate, James D Watson. He was succeeded by Francis Collins 
who headed the public sequencing effort while a private consortium (Celera) also undertook 
the challenge of sequencing the entire (haploid) human genome, an estimated three billion 
base pairs. The twin consortia announced the completion of the draft human genome in late 
2000 (public (Lander et al., 2001) and Celera (Venter et al., 2001)) although a so-called 
completed version was only announced in 2003. The templates for these human genomes 
were pooled DNA samples while the entire genome of a single individual was only 
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published in 2007 (Levy et al., 2007). However it is currently estimated that actually only 
93% of the human genome has been sequenced with repeat regions within telomeres and 
centromeres remaining outstanding. The public contribution to the first human genome is 
estimated to have cost US$3 billion. 
It was predicted prior to and during the project that the human genome would contain 
between 40,000 and 100,000 protein coding genes and this number would greatly exceed 
other mammals, explaining, in particular, our cognitive uniqueness. However, it now 
appears that we have only about 20,000 to 25,000 protein-coding genes (1-2% of the entire 
genome), a figure that is, not only similar to other mammals, but dwarfed by some plant 
species (International Human Genome Sequencing Consortium, 2004).  
In disease research we are particularly interested in the genetic variation between affected 
and unaffected individuals. As the sequencing of whole genomes for all the individuals in a 
research cohort remains prohibitively expensive, researchers have had use to methods that 
can approximate the total genetic variation. 
3.2 Genetic variation 
In monogenic forms of diseases such as AD, single, rare genetic polymorphisms that we 
commonly call mutations cause the disease. These mutations generally segregate in families 
or very rarely originate de novo in the germ line of our patient of interest (proband). The 
former have been, and will continue to be for the next few years at least, discovered by gene 
linkage studies in multi-generational families.  
In contrast most AD cases are regarded as sporadic with no familial or geographic 
clustering. They are also called idiopathic (literally unknown pathogenesis). However 
despite lacking a Mendelian pattern of inheritance we do know that genetics contributes to 
the susceptibility of sporadic AD. What we do not know for any particular sufferer is the 
magnitude of that genetic contribution or the number of genes involved. The ‘common 
variant’ hypothesis for complex diseases states that a variable number of commonly 
occurring gene variants combine to make up the genetic component of disease causation. A 
common variant or polymorphism is defined as one where the minor allele frequency is 
greater than 1% in the population.  
The most numerous genetic variants are single nucleotide polymorphisms (SNPs) and there 
are thought to be around 30 million SNPs in total meaning that two unrelated persons, 
chosen at random, will differ at about 1 in every 1,200 to 1,500 bases. In 2002 the National 
Institutes of Health started a $138 million project called the HapMap Project to catalogue the 
common SNPs in European, East Asian (Han Chinese and Japanese and African (Yoruba)) 
populations. By 2010 HapMap had released details of SNPs and inferred copy number 
polymorphisms in 1300 individuals from these four ethnic groups (Altshuler et al., 2010). As 
will be discussed below, this detailed data on human genetic variation combined with gene 
chip technology allows the simultaneous testing of more than 2 million SNPs in what are 
called genome wide-association studies (GWAs).  
The remaining ‘uncatalogued’ common variants will consist of rarer SNPs and smaller copy 
number variations (<500 base pairs) (Conrad et al., 2010). The ‘1000 human genome project’ 
aims to use next generation sequencing (NGS) to bridge this gap (The 1000 Genomes Project 
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Consortium, 2010). NGS has many current and potential applications in studying complex 
diseases and will be a recurring theme for the remainder of this chapter. 
3.3 Microarrays 
Microarrays (a generic term for a gene chip) are utilised for GWAs but they are more 
commonly known as a platform in genome-wide expression or transcriptomic studies. 
Microrrays were initially manufactured by printing the cDNAs of interest onto a glass 
microscope slide but now short oligonucleotides (probes) complementary to known exonic 
regions are directly synthesised onto a glass microscope slide or microscopic beads. Probes 
are typically designed to complement (bind to) the 3’ untranslated regions of transcripts 
although newer generation arrays have multiple probes across whole genes. The detection 
of signal with the microarray platform relies on probe-hybridisation and non-specific 
binding can potentially affect the relative detection of lowly expressed transcripts. Modern 
microarrays have around 50,000 probes representing the approximately 20,000 known 
protein coding genes, meaning there is redundancy for some genes. The accompanying 
software will usually report only the maximally expressed or maximally differentiated 
probe for each gene. The ability to make 20,000 comparisons in a single experiment is an 
extremely powerful and seductive tool that importantly makes no a priori hypotheses to the 
importance of any one gene. However, this number of comparisons always exceeds the 
number of individuals being sampled creating statistical dilemmas for the confident 
detection of real differences. This ‘curse of multidimensionality’ similarly affects the analysis 
of GWAs or any –omic platform (Somorjai et al., 2003). 
3.4 Next generation sequencing 
The sequencing of the human genome project was carried out using a technique called dye 
terminator chemistry developed by Fred Sanger 30 years before (Sanger et al., 1977). This 
technique relies on the amplification of the DNA sequence with incorporation of 
terminating dideoxynucleotides and the subsequent arrangement of all the fragments (now 
by software) to derive the final sequence. Although capable of long accurate reads (up to 
1500 bases) and eventually automated with capillary technology the technique was, by 
today’s standards, very slow.  
The term next generation sequencing (NGS) generically refers to platforms that allow the 
sequencing of several hundred thousand templates simultaneously (Margulies et al., 2005). 
For most NGS platforms the multiple templates are sequentially exposed to a known 
nucleotide whose attachment to its complementary base generates ATP, which is 
subsequently used to produce a luminescent signal. The signals across the array are 
captured as an image, before the excess nucleotides are washed away and the process 
repeated. The actual cycle number or read length is platform-dependent, but will vary from 
75 to about 400 bases. This in-parallel sequencing is obviously much quicker than the single-
sample Sanger method and now allows relatively small laboratories with a single 
instrument to perform whole genome sequencing that was, until very recently, the domain 
of dedicated sequencing centres. There are now also third generation sequencing systems 
based on single-molecule analysis. These promise to be quicker and cheaper than NGS 
platforms and more accurate due to longer read lengths although they may still not quite 
achieve the lengths seen with Sanger sequencing. 
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One of the major applications of NGS is full-length mRNA sequencing called RNA-Seq. 
Unlike microarrays RNA-Seq provides a digital readout of all transcripts including those 
that are lowly expressed and it does not rely on prior knowledge of the genome for probe 
design. Most current preparatory methods for RNA-Seq continue to use a PolyA fraction 
(mRNA) but total RNA methods, which require the deletion of the abundant architectural 
RNA species (ribosomal and transfer RNA), are improving. The latter allows the full 
repertoire of both coding and non-coding RNA to be quantified.  
3.5 Proteomics 
The term proteome describes the full complement of proteins, including post–translational 
variants, produced in a particular cell or tissue (Wilkins et al., 1996). For many biologists, 
proteins remain the key functional entities that can only be approximated by transcriptomic 
analyses. Certainly there is not necessarily a linear relationship between mRNA and 
proteins levels. In a generic proteomic analysis, the lysate would be separated by two-
dimensional gel electrophoresis and the ‘spots’ of interest excised, digested, and the 
resultant peptide fragments subjected to mass spectroscopy (MS). Individual spectra are 
compared to databases to derive peptide identity and by computation, the likely parent 
protein. This process is also referred to peptide mass fingerprinting. It is now more common 
to use tandem MS where a specific peptide is further fragmented and fragments subjected to 
MS (peptide fragmentation fingerprinting). Proteomics can be made semi-quantitative by 
spiking in stable isotopes as reporter ions allowing the relative abundance of the peptides in 
the overall spectra to be calculated. 
4. Pathogenesis 
Pathogenesis is defined as the series of events and mechanisms that result in the clinical 
manifestation of a disease. It encompasses the aetiological agent, its entry into the host 
and the subsequent host responses to that agent over time. In general the greater the 
‘dose’ of an aetiological agent, the more rapid will be the disease onset and severity. Host 
resistance or compensatory mechanisms will act to maintain homeostasis and so delay the 
disease onset and its impact, but an over exuberant or aberrant host response could also 
be a major factor in the clinical manifestation of the disease itself. Neurodegenerative 
diseases tend to be late-onset, around 75 years in the case of AD, with preclinical or 
prodromal periods of extended, but unknown, lengths. This type of disease history 
presents a number of pathogenic possibilities. In one scenario the aetiological agent(s) are 
extremely subtle and require a long time period to overcome host resistance. Alternatively 
host resistance may be entirely capable of dealing with the neurodegenerative agent until 
it fails due to old age. In the latter case a much shorter prodromal period would be 
expected. A variation on the latter theme is that rather than a foreign agent inducing the 
pathogenic process, it is a physiological process that goes awry because suitable checks 
and balances fail with advancing age. If the latter proved to be the case with AD then 
treatment strategies might be plagued by unwanted side effects.  
In the introduction we discussed that there are two major forms of AD, monogenic and 
sporadic. These types of AD are sometimes referred to early-onset (EOAD) and late onset 
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(LOAD), with 60 years of age often given as the arbitrary cut off. With reference to 
monogenic forms of AD we might think of mutations as an increased ‘dose’ (severity) of an 
aetiological agent and monogenic AD can present as young as 20 years of age. In fact, very 
rarely, AD-causing mutations are actually gene multiplications with direct gene dosage 
effects. 
Sporadic forms of a disease are defined by having no familial or geographic clustering but 
this term is slightly misleading because there is certainly a genetic component in these 
common forms of AD. Epidemiological studies suggest that AD sufferers have a 2.5 fold 
greater likelihood of family history of the disease (Sutherland et al., 2011b). In our ‘dose’ 
analogy above the late-onset nature of these common forms of AD would be consistent with 
common genetic variants, conferring only slight alterations to protein function or 
expression, being the causative agent. We also generally assume that the genetic component 
will be multifaceted with both additive and interactive relationships with environmental 
exposures. The latter refers to a scenario where a potential genetic risk factor only modifies 
disease risk if that individual has been exposed to a certain environmental stress. We will 
return to the discussion of AD genetics shortly but it is useful at this stage to introduce the 
amyloid precursor protein (APP) and its metabolite A.  
4.1 APP metabolism 
The A peptide was initially purified from amyloid-containing AD brain tissue (Glenner 
and Wong, 1984) and the cored plaques of AD and Down syndrome patients (Masters et al., 
1985). The parent protein, APP, was then isolated from a human brain cDNA library (Kang 
et al., 1987). The predicted 695 amino acid long protein with a single transmembrane domain 
was described as being similar to the prion protein, a hypothesised neuronal surface 
receptor. There are three major APP isoforms, 695, 751 and 770 amino acids in length with 
APP695 being the most common in neural tissue (Yoshikai et al., 1990). 
Following translation the APP protein is retained in the secretory pathway, and is 
transported to the cell membrane. The protein is subsequently degraded via proteolytic 
cleavage by either -, and -secretases or alternatively - and -secretases at the cell 
membrane or following the endocytosis of APP as part of normal membrane turnover 
(LaFerla et al., 2007). In addition a variable fraction of APP undergoes post-translational 
proteolytic cleavage within the secretory pathway. The -secretase is a multi-unit enzyme, 
that includes either the presenilin 1 (PS1) or presenilin 2 (PS2) proteins and it cleaves APP 
(and other proteins such as Notch) within its transmembrane domain. -secretase activity is 
carried out by a family of proteins (including ADAM 9) and this cleavage results in the 
secretion of an extracellular fragment of APP (sAPP-ǂ) and the retention of a C-terminal 
fragment (CTF) of 83 amino acids (Fig. 2). sAPP appears to act as a neuroprotectant, and 
has neurotrophic effects on synaptic plasticity (Postina, 2008). Alternatively, and mutually 
exclusive to -secretase cleavage, the -secretase enzyme (BACE1, also called Asp2, 
memapsin 2, is the major form in the brain) cleaves APP at variable sites about 16 amino 
acids proximal to the -secretase site (Vassar et al., 2009). The combination of -secretase and 
-secretase cleavages releases a variety of peptides that are collectively called A (1,2,3 to 39-
43) (Fig. 2).  
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Fig. 2. The structure of the amyloid precursor protein (APP770). This is a schematic diagram 
of the longest APP isoform (APP770). The -, -and -secretase sites are shown. APP 
undergoes physiological cleavage through two alternative pathways; -secretase or -
secretase. The latter pathway involves the cleavage of APP at  and  sites and results in the 
production of various A peptides. Cleavage at the  site prohibits the formation of the A 
peptides. The hydrophobic 29-40(2) segment of the A peptide is part of the transmembrane 
domain of APP and is likely to confer both aggregative and membrane–binding behaviour 
to these peptides (Sutherland, 2003, PhD thesis). 
The ǃ-secretase pathway is also called the amyloidogenic pathway because the major 
products A1-40 and A1-42 will rapidly aggregate with themselves in vitro and in vivo with 
A1-42 in particular capable of rapid self-assembly. A1-42 is known to be neurotoxic in vitro 
(Lorenzo and Yankner, 1994) and in vivo (see animal models below) and thought to be 
central to AD pathogenesis.  
Amyloid structures are composed of pairs of anti-parallel ǃ -strands or ǃ-pleated sheets of 
A. It was these fibrillar forms of A that were originally presumed to be pathogenic 
although oligomers are now generally regarded as the pathogenic form of A (Walsh et al., 
2002). Interestingly A is produced in proportion to synaptic activity and has the opposite 
effect to sAPP on synaptic connections (Selkoe, 2002). This could suggest an useful 
antagonistic action although A is still generally regarded purely as a degradative product. 
A is normally removed from the brain by the perivascular drainage of interstitial fluid to 
the cervical lymphatics (Weller et al., 2008) but is also actively secreted into the CSF.  
4.2 Monogenic forms 
The first AD family presenting with an apparent Mendelian pattern of inheritance was 
described in 1932 (Schottky, 1932). In more modern times a family was reported with 51 
affected persons in 8 generations (Nee et al., 1983). Down syndrome individuals who are 
trisomic for chromosome 21 (C21) and have 3 copies of the APP gene also develop A 
pathology (Heston, 1977). A gene dosage model was proposed for Down syndrome patients 
as an explanation for early presentation with AD-like pathological changes (Tanzi, 1989). 
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Early linkage studies of multiple large kindreds mapped a common genetic defect to the 
APP region of C21 (St George-Hyslop, 1987 #8988) although APP did not initially appear to 
be involved (Tanzi et al., 1987a; Tanzi et al., 1987b). Missense mutations in APP was 
eventually described in 1991(Goate et al., 1991) while the predicted duplications in the APP 
gene, given the gene dosage hypothesis for Down syndrome, were only discovered later 
(Rovelet-Lecrux et al., 2006). These cases also showed cerebral amyloid angiopathy, a disease 
entity that can occur independently of AD but is present in 80% of sporadic AD cases (Ellis 
et al., 1996). APP mutations themselves are very rare and it is the PSEN1 gene (encoding 
presenilin 1) where the majority of AD mutations have been detected (Sherrington, 1995 
#674). Mutations in the PSEN2 gene were also found in 1995 (Levy-Lahad et al., 1995) but 
these are also relatively uncommon (Bekris et al., 2010). In comparison to PSEN1 mutation 
carriers the PSEN 2 cases had a more variable phenotype, a later onset of disease and a 
reduced penetrance, but the ratio of Aǃ 1-42:Aǃ 1-40 is increased in all monogenic AD brains.  
One of the PSEN1 families (N141I mutation) was descended from Volga Germans who had 
immigrated to the USA. It was later suggested that these individuals were likely to originate 
from the same region of Germany as Auguste D (Yu, 2010 #8999) and perhaps she had the 
same mutation.  
4.3 Amyloid cascade hypothesis 
There is almost irrefutable proof that monogenic forms of AD result from the aberrant 
production or metabolism of the A peptides and these rare forms are, apart from the earlier 
age at onset, phenotypically very similar to the sporadic forms (Shepherd et al., 2009). This 
similarity was the major driver for Hardy and Higgins to propose the amyloid cascade 
hypothesis for the pathogenesis of sporadic AD in 1992. This hypothesis suggested that the 
neurotoxic A sets up a cascade of events in adjacent neurons resulting in NFT formation 
and neuronal death. How A actually precipitates these events was not articulated but most 
interpreted the hypothesis as suggesting that it was A fibrils in the form of plaques that 
were the neurotoxic entity. Later amendments to the hypothesis suggested that it was more 
likely to be A1-42 oligomers rather than fibrils but whether these interact directly with the 
neuronal cell membrane or via receptors was still unknown (Hardy and Selkoe, 2002). The 
cascade hypothesis remains the most popular working hypothesis for AD pathogenesis and 
is the underlying basis for proposed preclinical diagnostic criteria and the vast majority of 
treatments under development (Sperling et al., 2011). Nevertheless, it is not quite 
unanimously accepted. Distracters, in particular, point to the fact that NFTs rather than 
amyloid are initially deposited in the memory-associated hippocampus and that the 
regional progression of NFTs is a better correlate of disease symptoms and severity (Braak 
and Braak, 1991). Furthermore the latest GWAs also hint at A-independent mechanisms for 
sporadic forms of the disease (discussed below). 
The monogenic forms of AD have also allowed the production of animal models, the main 
research workhorse towards understanding pathogenesis. A brief synopsis of the mice 
models is given below but the area has been extensively reviewed by Gotz and Ittner (Gotz 
and Ittner, 2008) including a thorough consideration of how invertebrate models such the 
fruitfly (Drosophila melogaster) and the worm, Caenorhabditis elegans, have also impacted on 
AD research.  
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The transgenic expression of human mutant APP in mice (Games et al., 1995) caused plaques 
and inflammatory responses but not tangles or any substantial neuronal loss. These mice 
were subsequently crossed with a variety of gene knockout strains including an 
apolipoprotein E (APOE) null mouse where a dramatic reduction in A load was seen (Bales 
et al., 1997). As we will discuss shortly, the possession of the 4 variant of the APOE gene is a 
leading risk factor for sporadic AD. Holtzman and colleagues were then able to show in 
these mice that the additional expression of human APOE 4 produced a 10-fold greater 
increase in A deposits than APOE 3 (Holtzman et al., 2000). A double transgenic mouse 
was subsequently developed with both APP and PSEN1 mutant forms and this showed both 
an acceleration of A deposition and an increased quantity of A load over either parent 
mutant mouse (Holcomb et al., 1998).  
A-orientated studies have dominated the AD field but there has always been a sub-
community of researchers that have investigated the role of tau. The first tau transgenic 
mouse was produced in 1995 and showed that exogenous tau was redistributed away from 
the axon and hyperphosphorylated in a ‘pre-tangle’ state (Gotz et al., 1995). Although no 
mutations in the tau gene (MAPT) have been found in AD patients, tau mutations have been 
described in a familial form of frontotemporal dementia proving that mutant tau is 
sufficient for neurodegeneration (Hutton et al., 1998). The first mutant tau mouse strain was 
produced in 2000 (Lewis et al., 2000) and then a double mutant APP/tau cross was produced 
in 2001 with the expectation that this would be an accurate phenocopy of AD (Lewis et al., 
2001). This double mutant showed the same A pathology as the APP mutant mouse but 
greater NFT pathology than the parent mutant tau mouse strain and greater neuronal loss. 
This suggested a potential interaction between A and tau, a possibility strengthened by the 
demonstration that the intracerebral injection of Aǃ1-42, had the same precipitating effect on 
tau pathology in a second mutant tau strain (Gotz et al., 2001) 
It was with the generation of a triple transgenic mouse (APP /tau/PSEN1) that a model that 
closely recapitulated human AD pathology became available (Oddo et al., 2003). 
Furthermore A deposition preceded tangle formation in this model supporting the amyloid 
cascade hypothesis. 
The cascade hypothesis does not suggest a direct interaction between tau and A but rather 
that an extracellular A build up eventually results in altered neuronal tau kinase and 
phosphatase activity precipitating tau hyperphosphorylation (Hardy and Selkoe, 2002). 
However support for such a direct interaction came from in vitro studies where A in the 
presence of tau forms fibrillar aggregates containing both molecules (Giaccone et al., 1996). 
Of course such an interaction would require the intraneuronal build up of A, a hypothesis 
that remains largely left field despite reasonable evidence supporting it (D'Andrea et al., 
2001; LaFerla et al., 2007; Gouras et al., 2010).  
A particularly interesting finding was that ‘neurotoxic’ A failed to cause degeneration of 
neuronal cultures from tau null mice (Rapoport et al., 2002). In 2007 a similar effect was 
demonstrated in a mouse over-expressing human APP where behavioral deficits were 
attenuated on a tau null background (Roberson et al., 2007). As tau did not reduce the levels 
of APP or A the authors surmised that it must ‘uncouple Aǃ from downstream pathogenic 
mechanisms’. They were able to rule out A-mediated modifications of tau such as 
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hyperphosphorylation or truncation as the mechanism. It seemed that tau was sensitising 
the mice to A-mediated over excitation and potential excitotoxicity.  
Excitotoxicity in the brain can result from overactivation of N-methyl-D-aspartate (NMDA) 
receptors (NRs) and it has been postulated that A causes excitotoxicity through a NR-
mediated mechanism (Snyder et al., 2005). Under normal conditions the phosphorylation of 
these NRs by kinases such as Fyn facilitate interactions with post-synaptic density protein 
95, the necessary conduit in the perpetuation of the excitatory signal. Interestingly increased 
Fyn expression was known to exacerbate toxicity in APP transgenic mice (Chin et al., 2005). 
These factors all appeared unrelated until Ittner and colleagues showed in a dysfunctional 
tau mouse model, that when the tau-mediated dendritic transport of Fyn was prevented, 
A-mediated excitotoxicity and premature lethality was attenuated (Ittner et al., 2010).  
It remains unclear how A actually decreases the threshold for glutamate excitotoxicity but 
it is not thought to be through direct binding to the NRs (Snyder et al., 2005). Nevertheless 
the NR antagonist, memantine is considered to act by blocking A-neurotoxicity (Miguel-
Hidalgo et al., 2002). 
4.4 Sporadic forms and the APOE 4 genotype  
There are very few factors, genetic or environmental, that have reproducibly been shown to 
modify the risk for sporadic forms of AD. Age, family history, female gender, low 
education, head injury and type II diabetes seem to increase risk. While long-term anti-
inflammatory use and performing mental and physical activity seems to be protective. This 
area has been recently reviewed (Sutherland et al., 2011b). The finding of AD prevalence 
being inversely associated with education led to the idea of non-demented aged individuals 
having a ‘cognitive reserve’ (Stern et al., 1994). This hypothesis suggests that the more our 
brains are utilised the better they are able to withstand or perhaps more accurately 
compensate for, increasing AD pathology. Nevertheless, apart from ageing itself, all these 
factors have been shown to have very minor effects on AD risk.  
One notable exception here is the possession of the APOE ε4 allele which could account for 
as much as 50% of the attributed risk in AD (Ashford, 2004). This effect was first described 
in 1993 (Corder et al., 1993) but it is still not known how this common variant actually 
modifies disease risk. ApoE is the major apolipoprotein of the brain and its primary role is 
the delivery of lipids and particularly cholesterol to neurons from astrocytes. There are 
three major protein isoforms (ε2/3/4) based on their respective positions when separated 
by isoelectric focussing (IEF) (Zellner et al., 2009). The variants are generated by two non-
synonymous single nucleotide polymorphisms (SNPs) in exon 3 of the gene, rs429358 and 
rs7412. Alternative cytosine or thymine bases at these sites leads to either arginine or 
cysteine at positions 112 and 158 in apoE protein, respectively. The apoE 4 isoform has 
arginine at both positions and varies from the common 3 isoform in both its binding 
affinities (Weisgraber et al., 1982) and degradation properties (Fukumoto et al., 2003; 
Riddell et al., 2008). The risk of sporadic AD increases with the dose of the APOE 4 allele; 
heterozygotes are at a two-fold higher risk but 4 homozygotes are at a greater than 12-
fold risk (Corder et al., 1993). There is a similar effect on the age at disease onset with an 
estimated decrease of 7-9 years per allele (Chapman et al., 2001). However, possession of 
this allele is neither essential nor sufficient for AD. ApoE ε4 has an increased binding 
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efficiency for A (Strittmatter et al., 1993) and can accelerate A fibril formation in vitro 
(Castano et al., 1995). It is therefore generally interpreted that the apoE 4 isoform 
modifies AD risk by accelerating the development of plaques although it is probably a 
more complex association between neuronal lipid content and amyloid precursor protein 
metabolism (Grosgen et al., 2010).  
Before the arrival of GWAs, a meta-analysis of single candidate gene studies showed that, 
apart from APOE, very few other gene loci modified AD risk and their effects were all very 
modest (odds ratios ~1.25) (Bertram et al., 2008). The first GWAs in 2007 essentially 
confirmed these findings (Grupe et al., 2007; Reiman et al., 2007)  
Subsequent GWAs would concentrate on defining the non-APOE genetic component of AD 
and in 2009 two independent studies reported an association with a second apolipoprotein-
encoding gene, CLU, which encodes clusterin or apoJ and a gene called PiCALM (which 
encodes phosphatidylinositol binding clathrin assembly protein) (Harold et al., 2009; 
Lambert et al., 2009). Clusterin is best known as a chaperone protein but as its alternative 
name suggests it is also found in lipoprotein particles and regulates cholesterol and lipid 
metabolism in the brain (Nuutinen et al., 2009). A feature of these later GWAs were their 
two-tiered approach where only SNPs deemed significant in a first cohort were tested in an 
additional independent cohort and only those replicated in both reported as significant. This 
strategy reduced the multidimensionality of the study and theoretically the risk of 
generating false positives. Lambert and colleagues also found an additional association with 
the CR1 gene, encoding a complement receptor (Lambert et al., 2009).  
In 2011 two further GWAs were reported that combined these multi-tier approaches with 
meta-analyses of additional data sets to further increase their detection sensitivity 
(Hollingworth et al., 2011; Naj et al., 2011). In combination these 2011 studies confirmed 10 
significant loci associated with sporadic AD included the genes previously described 
(APOE, CLU, PICALM and CR1). One of the co-authors from these studies suggested that 
these 10 genes implicate three pathways in AD pathogenesis, immune system function, 
cholesterol metabolism and synaptic cell membrane processes (Morgan, 2011). He further 
suggested that these pathways appear to be largely A-independent. However A is known 
to inhibit synaptic activity and A can bind to membranes where it may actually modulate 
the lipid make-up including cholesterol content (Grimm et al., 2005).  
Morgan considers that GWAs have now accounted for up to 50% of genetic risk in sporadic 
AD (Morgan, 2011). The question remains what has happened to the missing heritability? 
SNP arrays detect common variants (SNP directly and copy number variants by inference) 
but there is an alternative hypothesis that a large proportion of AD cases will result from 
rare variants in many different genes (Pritchard, 2001). Alternatively, Cooper and Shendure 
argue that it is not the GWAs technology that is limiting detection of common variants but 
rather our interpretation of the data (Cooper and Shendure, 2011). They maintain that an 
improvement in ‘probability’ is required before such studies will reach their maximum 
detection potential. This means that the analysis needs to be limited to functional entities 
only to reduce the number of tests carried out. They admit that defining which SNPs are 
functional (or in close linkage disequilibrium with such SNPs) remains a ‘work in progress’ 
but report steady advances in both computational approaches that predict changes in 
protein structure in non-synonymous SNPs and multiplex experimental approaches that 
combine mutagenesised libraries, in vitro transcription and RNA-Seq.  
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Two other factors potentially lowering the power of GWAs are not platform-related at all. 
As discussed above AD pathology is present in 30% or more of our age-matched controls 
and there are variations in the clinical presentation of AD. In particular it seems highly 
probable that individuals who develop clinical variations such as posterior cortical 
atrophy or logopenic aphasia will have different underlying genetic susceptibilities. It is 
hoped that biomarkers will be able to facilitate more focused comparisons of AD sub-
groups or allow the dichotomous case-control paradigm to be replaced by an 
investigations of a continuous variable such as amyloid load using positive electron 
tomography (PET) (Sutherland et al., 2011b). 
4.5 Transcriptomics and brain tissue 
Most readers will associate the term ‘microarray’ with whole genome expression studies. 
Microarray (expression) studies have been extensively used over the last decade for the 
analysis of human tissue and animal models. As discussed above, researchers were 
expecting a relatively high 40 to 100,000 protein-encoding genes in the human genome. This 
expectation was largely based on the evolutionarily complex human brain. However 
comparative genomic analyses have now shown that the increase in complexity and 
specialisation of the human brain is largely derived at the level of transcription (Enard et al., 
2002). This includes the utilisation of variable length 3’ untranslated regions (Ramskold et 
al., 2009) and alternatively spliced isoforms (Pan et al., 2008; Wang et al., 2008). This 
transcriptomic diversity will underlie both brain function and presumably dysfunction, 
making the transcriptomic analysis of postmortem human brain tissue a seemingly ideal 
experimental paradigm to find pathogenic clues in AD.  
A meta-analysis of microarray studies in AD utilising brain tissue has not been undertaken 
but a review of reported finding suggests that these studies have been largely discordant 
and disappointingly have not provided novel clues about AD pathogenesis (Courtney et al., 
2010). These divergent findings may be due to a number of different factors. High RNA 
quality is the major factor in the subsequent quality of microarray data. Brain tissue pH is 
the major determinant of RNA quality but unfortunately it is the agonal period that is 
critical in determining pH, and this is both long in neurodegenerative disease and out of the 
control of the researcher. In comparison to animal or cell culture models RNA quality is 
invariably poorer from postmortem brain tissue (Preece and Cairns, 2003). The study of 
postmortem tissue is also inherently a retrospective analysis. The time component of 
neurodegenerative diseases means many rounds of tissue insult and compensatory host 
responses will have occurred, particularly in regions such as the entorhinal cortex in AD. 
The pathology in the postmortem brain may have little informative value on what 
precipitated the disease at the transcriptomic level. In other words it becomes impossible to 
delineate disease  ‘cause’ from ‘effect’. 
Variability in microarray studies may also reflect limitations in the technology itself 
(Sutherland et al., 2011a). A new NGS-based platform promises to address most of these 
issues and is discussed immediately below, but prior to this let us briefly look at a 
combination of the two main methodologies discussed above, GWA and expression studies. 
These can be combined to derive expression quantitative trait loci (eQTL). In a direct 
experiment approach genomic DNA of a case-control cohort will be assayed by SNP array 
while expression analysis will be carried out on say, RNA from peripheral leucocytes of the 
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same individuals. The expression of each individual transcript can be regarded as an 
independent variable and tested against all the SNPs on the GWAs array. This experiment 
can detect ‘cis’ effects of SNPs influencing the expression of their own gene but also ‘trans’ 
effects of SNPs that are spatially disparate from the gene of interest. 
Alternatively an indirect approach can be used where the expression analysis is carried out 
in the brain tissue of neuropathologically confirmed cases and controls while the GWAs is in 
an independent AD cohort from (ideally) the same population. Such an indirect study has 
been carried out in AD and their major findings were three SNPs that associated 
significantly with IDE (insulin degrading enzyme) expression levels. This is a very 
interesting finding as IDE actually degrades A (Kurochkin and Goto, 1994) and a meta-
analysis, although not the latest GWAs, suggests that it is associated with sporadic AD 
(Bertram et al., 2007). Presumably such studies will soon be reported with the partial or 
complete use of NGS. 
4.6 RNA-Seq 
As will be seen in the next section of this chapter NGS will influence nearly all aspects of 
research on disease pathogenesis. However it may have the greatest impact in trancriptomic 
analysis (Sutherland et al., 2011a). In comparison to microarrays, RNA-Seq with its linear 
dynamic range and sensitivity for expression changes in low-abundant transcripts, provides 
a much more accurate (digital) signal. All transcripts can be confidently assumed to be 
present regardless of their level of expression. Second, microarrays rely on known genomic 
sequences for their probe design whereas RNA-Seq, with no such limitation, can detect 
novel transcripts (Cloonan and Grimmond, 2008). Third, microarrays generally quantify 
only the total transcripts for each gene but RNA-Seq, with its single base resolution, can 
detect the exact location of transcription boundaries allowing all transcriptional outputs to 
be quantified. This includes variants due to alternative promoter usage, splicing patterns 
and 3’ UTR lengths that are unique to the human brain. A recent ‘proof of concept’ RNA-Seq 
study compared commercial RNA samples from AD patients with pooled control samples 
(Twine et al., 2011). One of their major findings was the dysregulation of APOE transcription 
in the temporal lobe of an AD patient. SNPs in and around the APOE gene seemingly 
associate with AD independently of the ε4 effect, although there is a 7 kb linkage 
disequilibrium block that covers the entire APOE gene locus (Belbin et al., 2007). It is 
anticipated that more RNA-Seq studies of postmortem brain tissue will appear in the 
literature in the near future. 
4.7 Proteomics 
The application of proteomics to AD has involved analyses of CSF, plasma and postmortem 
brain tissue. The driver for this research is to find biomarkers or a proteomic signature to 
improve AD diagnosis and potentially allow preclinical diagnosis (Zellner et al., 2009). 
It has been known for sometime that there are protein-based alterations in the CSF profile of 
AD patients. Given the role of excess A1-42 in the disease it is perhaps surprisingly to see 
that this specific peptide is reduced in patient (clinical) analytes (Blennow and Hampel, 
2003). This has been explained by the pathogenic retention of A1-42 in the parenchyma 
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facilitating plaque development. However there are increases seen in both phosphorylated 
tau species and total tau in AD patients’ CSF. 
A proteomic study that utilised two-dimensional gel electrophoresis (2-DE) found 23 
differentially expressed proteins in the CSF of AD patients (Finehout et al., 2007). These 
included a down-regulation of apoE (but they did not identify A or tau). The sampling of 
CSF is relatively straightforward but it is not without risk of infection or spinal cord 
damage. There are also important ethical considerations in consenting dementia patients for 
such procedures although this issue also extends across the breadth of potential clinical 
research.  
Researchers and clinicians are therefore keen to find brain-specific (and disease-specific) 
patterns of expression in serum or plasma samples that are more easily sampled and can be 
sampled repeatedly during the course of the disease. A disease-specific pattern in peripheral 
samples could reflect a number of scenarios; pathogenic species have drained or potentially 
leaked from the brain, there are systemic manifestations of the disease process or the 
functional consequences of underlying genetic susceptibility can be detected peripherally. 
As the brain is behind the relatively impermeable blood-brain barrier, leaked metabolites 
are unlikely to contribute greatly to plasma. Nevertheless the proteins, complement factor H 
and ǂ-2 macroglobulin have been detected in plasma using by 2-DE and immunochemical 
assays although their sensitivity (62%) and specificity (60%) is far below those required for a 
biomarker (Hye et al., 2006). In a recent study the reduced levels of apoE seen in the CSF, 
have also been seen in plasma of early stage AD sufferers, and particularly in APOE 4 
carriers. The decrease in apoE levels was inversely correlated with A load seen on PET 
(Gupta et al., 2011). 
5. Future 
As we contemplate the future of research in AD, it is worthwhile reiterating that there are 
currently no treatments that slow the progression of the disease. At their first clinical 
presentation AD sufferers will already have significant neuronal loss. Ideally, 
neuroprotective agents are required but these would still be relatively ineffective if only 
implemented at the onset of clinical signs. A successful treatment regime is dependent on 
the co-discovery of a therapeutic target(s) and a preclinical biomarker(s). These, in turn, are 
both predicated on gaining a greater understanding of early pathogenic events.  
5.1 Advances in understanding pathogenesis 
Without doubt the major technological advance in biology is NGS. It seems only a matter of 
time before the much-anticipated ‘$1000 genome’ is standard practice in both research and 
clinical practice (Pareek et al., 2011). Furthermore NGS is about to become third generation 
sequencing where nucleic acids are sequenced without the need for preparatory PCR 
amplification of templates, a procedure that potentially introduces biases. These ‘third-gen’ 
technologies run at nanoscale proportions and rely on either detecting the exonuclease 
cleavage of a specific nucleotide from the template or their incorporation into a newly 
synthesised DNA strand. It is predicted that these new platforms will achieve read lengths 
of around 1000 base pairs making the subsequent alignment to a reference genome a more 
rapid and accurate process. 
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In terms of AD research, NGS will spell the end of the current design of GWAs. All study 
subjects will soon be sequenced directly allowing both the ‘rare’ and ‘common variant’ 
hypotheses to be simultaneously tested. We are already seeing an intermediate combination 
of SNP global analyses with more focused sequencing efforts (Lupton et al., 2011). For 
example, an investigation of hypertriglyceridemic patients by GWAs followed by the 
resequencing of candidate genes uncovered a significant burden of rare variants (Johansen 
et al., 2010). 
It is interesting to postulate whether the knowledge of all genetic variation between affected 
and unaffected individuals (in a cohort) will deliver us the complete understanding of AD 
pathogenesis. There is no doubt that we will uncover hitherto unknown genetic clues that 
could increase our focus towards one defective pathway. However the single mutation in 
the autosomal-dominant inherited Huntington’s disease was discovered in 1993 (The 
Huntington's Disease Collaborative Research Group, 1993) and much remains to be known 
about the functional ramifications of that defect.  
In terms of transcriptomics, RNA-Seq templates usually involve polyA pre-selection so that 
only the mRNA fraction is sequenced however total RNA approaches are available where 
ribosomal RNA, which accounts for as much as 90% of the transcriptome, is selectively 
depleted. The move to total RNA approaches seems prudent given the increasing 
importance of non-coding and non-polyadenylated RNA species in biology (Mattick et al., 
2010) and the human brain in particular (Mattick, 2011). Non-coding RNA is transcribed 
from what was previously called ‘junk’ DNA and there is an amazingly diverse and 
continually expanding list of different RNA species being discovered. Perhaps more 
daunting is that single RNA molecules can also exist as structural variants with different 
functional roles (Wan et al., 2011). Notwithstanding the latter, the RNA-Seq platform finally 
gives us the opportunity to comprehensively investigate the transcriptome of the human 
brain (Sutherland et al., 2011a).  
5.2 Diagnosis 
When the first comprehensive criteria for clinical diagnosis were formulated in 1984, the 
only imaging modality in routine use in neurology was computer-assisted tomography. 
Neuroimaging has come a long way since then with volumetric magnetic resonance imaging 
(MRI), functional MRI including diffusion tensor imaging, single-photon emission 
computed tomography (SPECT) and PET with the amyloid-binding ligand, 11C-Pittsburgh 
Compound B (PiB-PET) and brain glucose metabolism (FDG-PET)) all been applied to AD 
patients. Neuroimaging in AD has recently been the subject of a large international 
public/private partnership, based in the USA (Weiner et al., 2010). Established in 2004, the 
Alzheimer's disease neuroimaging initiative (ADNI) seeks to validate MRI and PET images, 
in combination with CSF/blood biomarkers, as predictors and outcomes for use in clinical 
trials of AD treatments. They had a particular interest in establishing the criteria for 
preclinical AD and so recruited elderly controls and MCI patients, as well as AD sufferers, 
and followed them prospectively. ADNI consider, as per the amyloid cascade hypothesis, 
that the earliest detectable changes in at risk individuals are related to A. Moreover there is 
a detectable initial increase in CSF A1-42 (preclinical) and amyloid deposition using PiB-
PET. As discussed above these changes have been included in preclinical criteria but only 
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for use in a research context at this stage (Sperling et al., 2011). When this detectable change 
in A metabolism actually begins is unknown but decreases in CSF A1-42 are seen as early 
as the 6th decade in apoE 4 carriers and their age-related decrease is more severe (Peskind et 
al., 2006). Similarly PiB imaging of nondemented aged persons in Australia suggested that 
33% of healthy controls had high PiB binding (Rowe et al., 2010). Interesting a correlation 
between PiB binding and cognition was only seen in APOE 4 carriers.  
The increases in CSF phosphorylated and total tau are generally considered a later disease 
marker of the disease representative of neuronal degeneration, and likely to coincide with 
brain atrophy, hypometabolism or hypoperfusion on imaging (Weiner et al., 2010). However 
at least one study of MCI suggests that by this stage there are already decreases in CSF A1-
42 and increases in tau (Herukka et al., 2005). Rowe and colleagues suggested that A 
deposition (and increased CSF tau) are probably inevitable with ageing and other factors are 
involved in conversion to dementia (Rowe et al., 2010). 
5.3 Treatments in development 
Although not the subject of this chapter it would seem remiss not to touch on the excitement 
currently generated by stem cell technology in medical research. The possibility of 
regenerative medicine in neurodegenerative disease has been stimulated by the 
demonstration of neurogenesis in the human adult brain (Eriksson et al., 1998), the induction 
of stem cells from differentiated adult cells (Takahashi et al., 2007) and the conversion of 
these cells to mature phenotypes such as dopaminergic (Soldner et al., 2009) and motor 
neurons (Dimos et al., 2008). Regenerative medicine or cell transplantation therapies may 
prove efficacious in many diseases although the chances in AD, with its extensive neuronal 
loss, do appear more remote. A therapy promoting endogenous neurogenesis looks more 
promising and its stimulation through physical activity or environmental enrichment seen 
in animal models may yet underlie the ‘cognitive reserve’ hypothesis. Furthermore the 
potential for modelling AD using patient-derived cell lines is an exciting field with 
applications in understanding basic pathogenesis through to preclinical drug screening and 
clinical toxicity studies (Sutherland and Sidhu, 2011). 
The mechanism of action for the majority of drugs in current Phase II or III clinical trials is 
limiting the production or increasing the clearance of A (Gravitz, 2011). These include 
antibodies to A, inhibitors of A aggregation and inhibitors of -secretase. In comparison 
inhibitors of -secretase have proved more difficult to develop because of difficulties 
crossing the blood-brain-barrier and their poor affinity for the catalytic site, but two reports 
suggest that these roadblocks may have been solved (Atwal et al., 2011; Yu et al., 2011).  
Two of the four drugs in Phase III trials, bapineuzumab and solanezumab are humanised 
monoclonal antibodies (derived from murine antibodies). These passive immunisation 
strategies were developed when initial studies testing an aggregated A vaccine were 
abandoned due to 6% of the participants developing sterile meningoencephalitis (Orgogozo 
et al., 2003). An A vaccine had previously removed and prevented plaques in mutant APP 
transgenic mice, (Schenk et al., 1999) and reversed their learning deficits (Janus et al., 2000; 
Dodart et al., 2002). Passive immunisation seemed to have a similar effect in mice but the 
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earliest reports from human trials suggest that, despite reducing amyloid load, these 
strategies have no effect on cognitive function (Rinne et al., 2010). Furthermore trials 
determining the efficacy and safety of the -secretase inhibitor, semagacestat, had to be 
terminated due to actual cognitive decline (Cummings, 2010). 
These results have been seen by some as serious threats to the validity of the amyloid 
cascade hypothesis in sporadic AD, although proponents have countered these criticisms by 
arguing that A therapy is failing because it is instituted too late in the disease process 
(Gandy, 2011; Golde et al., 2011). They maintain that A therapy needs to be instituted as a 
prophylaxis and this, of course, means the preclinical identification of future AD patients 
and the treatment, or at least testing, of individuals without symptoms (Golde et al., 2011). 
According to Golde, Schneider and Koo, and based on the findings from imaging and CSF 
biomarker studies described above, individuals destined to have AD show detectable A 
deposition at least 10 years earlier. Furthermore amyloid plaques visualized by radioligand 
imaging and low CSF A1-42 can be monitored throughout potential trials of A therapies. It 
is not clear how an original cohort might be selected but aged APOE 4 carriers were 
suggested for screening (Golde et al., 2011). This hypothesized approach raises some very 
interesting ethical questions, not to mention changes required to regulatory criteria that are 
currently based on clinical symptoms.  
5.4 Preventive health 
Epidemiological studies were instrumental in establishing the connection between serum 
lipid levels, particularly high cholesterol, and coronary heart disease. Proponents of 
prophylactic A immunotherapy might argue that their proposal is similar to the current 
use of statins in reducing blood cholesterol. However epidemiological studies have been 
relatively unsuccessful in finding factors that modify the risk for AD, meaning that any 
proposed preventative strategies remain speculative at best.  
The statins story is an interesting one because individuals in the initial trials for heart 
disease appeared to have a reduced incidence of AD (Jick et al., 2000; Wolozin et al., 2000). 
This led to considerable research into cardiovascular risk factors in AD including 
hypertension, elevated serum cholesterol, smoking middle age obesity and type II diabetes. 
Interesting only type II diabetes survives meta-analyses (Sutherland et al., 2011b).  
Remaining physically and mentally active does seem to be relatively effective but it is likely 
that a cognitive reserve allows individuals to starve off the effects of AD pathology rather 
than decreasing the pathology itself. Of course this would still be an effective method to 
reduce the societal burden of AD.  
Despite all the research, the current situation in AD could still be summarised by the 
following paragraph from a recent commentary in the Journal supplement, Nature Outlook: 
“A big part of the problem is that researchers don't know enough about the biology of Alzheimer's 
disease to identify the right targets. The disease is the result of a long chain of events, but some of the 
links in that chain are still a mystery — nobody is certain which link to cut to stop disease 
progression” (Gravitz, 2011). 
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6. Conclusion 
Given the passage above the reader may become overly pessimistic about the possibilities 
for a cure of Alzheimer’s in the immediate future. In its general use the term ‘cure’ implies 
that there is a readily identifiable agent that causes AD and that this agent can be attenuated 
or even removed without any serious deleterious effects to the sufferer. 
All AD research to date suggests that there is no clear single aetiology for the majority of 
sufferers. The major pathogenic hypothesis is that in susceptible individuals, on a 
background of ageing, there is an increased production or decreased clearance 
(Mawuenyega et al., 2010) of a normal ‘degradative’ product called A whose build up in 
the brain becomes neurotoxic. 
An alternative or adjunctive interpretation is that A has a physiological role in the brain, 
perhaps synaptic pruning or inhibiting excitatory activity and that A metabolism itself 
becomes dysregulated in response to an unknown aetiological factor. The individuals who 
develop AD may have a greater propensity to deposit A or are less resistance to its 
downstream effects. In the latter scenario, monogenic forms of AD could still explained by a 
greater propensity to oligomerisation and deposition. The caveat is that prophylactic A 
immunotherapy may prove to have more serious side effects than if A is just a degradative 
product.  
The amyloid cascade hypothesis is a very good one that no doubt encapsulates important 
aspects of the pathogenesis of sporadic AD. However technological advances such as GWAs 
suggests that A-independent mechanisms are (also) important in AD while RNA-Seq is 
only now offering a methodology where the transcriptome of the human brain can actually 
be comprehensively examined. It therefore seems too premature to place all our therapeutic 
eggs in the A cascade basket. 
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